胃癌表型与5p15.33位点等位基因丢失相关性研究

目的 探讨胃癌5p15．33区微卫星标记杂合性缺失（LOH）与临床病理学表型的相关性。方法 抽提80例胃癌标本及其配对正常胃黏膜中基因组DNA，应用4个微卫星标记对5p15．33区进行LOH检测并与Lauren分型等临床病理学指标分析。结果 有76例临床信息齐全病例纳入统计分析。5p15．33区4个微卫星标记平均信息性病例比例为71．05％。其中31．58％（24／76）病例至少一个位点检测到LOH，以D5S2849位点LOH频率最高（37．25％）。5p15．33位点LOH以肠型胃癌多见（P〈0．01），与年龄、性别、部位、肿瘤大小、TNM分期及有无淋巴结转移无明显关系。结论 5p15．33区可能存在控制胃癌形态学表型的候选抑癌基因，但该基因可能不是决定其他临床表型的主要基因。

Analysis of correlation between allelotype of 5p15.33 with clinicopathological phenotypes in gastric cancer

Objective To explore the relationship between loss of heterozygosity (LOH) of 5p15.33 and the clinicopathological phenotypes in gastric cancer. Methods Genomic DNA was extracted from 80 pairs of tumor and adjacent normal tissues of gastric cancer and 4 polymorphic microsatellite markers for 5p15.33 were used for LOH analysis.Histological type of gastric cancer was defined as intestinal type or diffuse type according to Lauren's classification. Results Seventy-six cases were included in final analysis based on their clinical information.The average informative ratio of the 4 markers was 71.05%.Twenty-four out of 76 cases (31.58%) had LOH in at least one marker.The highest LOH frequency occurred at D5S2849 (37.25%).5p15.33 LOH was easily identified in intestinal type gastric cancer than that in diffuse type one (P< 0.01),but not related with age,gender,location,tumor size,TNM staging and lymph node metastasis. Conclusion Some morphological phenotype-related candidate tumor suppressive genes may locate in 5p15.33 region.However,other clinical phenotypes of gastric cancer may be not regulated by these candidate genes.